Cargando…
Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy
BACKGROUND: Oesophageal cancer (OC) survival rates have improved since the widespread adoption of neoadjuvant chemoradiation therapy (NACRT) followed by oesophagectomy (trimodality therapy). Unfortunately, the overall prognosis for patients with locally advanced disease remains poor. In this study,...
Autores principales: | Nevala-Plagemann, Christopher, Francis, Samual, Cavalieri, Courtney, Tao, Randa, Whisenant, Jonathan, Glasgow, Robert, Scaife, Courtney, Lloyd, Shane, Garrido-Laguna, Ignacio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069924/ https://www.ncbi.nlm.nih.gov/pubmed/30094072 http://dx.doi.org/10.1136/esmoopen-2018-000386 |
Ejemplares similares
-
Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma
por: Iyengar, Siddharth, et al.
Publicado: (2021) -
The Implications of Treatment Delays in Adjuvant Therapy for Resected Cholangiocarcinoma Patients
por: Parsons, Matthew, et al.
Publicado: (2022) -
Survival of patients with metastatic HER2 positive gastro-oesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on front-line chemotherapy plus trastuzumab
por: Nevala-Plagemann, Christopher, et al.
Publicado: (2019) -
Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins
por: Torgeson, Anna, et al.
Publicado: (2018) -
The impact of squamous cell carcinoma histology on outcomes in nonmetastatic pancreatic cancer
por: Gruhl, Joshua D., et al.
Publicado: (2020)